SANA platforms advance toward clinical trials for diabetes and cancer
Hypoimmune islet cell technology is advancing as a potential functional cure for type 1 diabetes, citing long-term cell survival and immune evasion without immunosuppression. Its in vivo fusosome CAR T platform is moving toward first-in-human trials for cancer.
Hypoimmune islet cell technology is presented as a potential functional cure for type 1 diabetes, with clinical validation showing long-term cell survival and immune evasion without immunosuppression. In vivo CAR T cell platforms using fusosome technology are advancing toward first-in-human trials for cancer.